Bombesin is a tetradecapeptide (14 amino acids) first isolated in 1971 by Anastasi and colleagues from the skin of the European fire-bellied toad Bombina bombina. Its mammalian counterpart, gastrin-releasing peptide (GRP), is a 27-amino acid neuropeptide that shares bombesin's C-terminal heptapeptide sequence — the critical region for receptor binding and biological activity.

Overview

The bombesin peptide family comprises three mammalian members: gastrin-releasing peptide (GRP), neuromedin B (NMB), and an orphan receptor ligand (BRS-3 ligand, not yet isolated). These peptides signal through three receptor subtypes: BB1 (NMB receptor/NMBR), BB2 (GRP receptor/GRPR), and BB3 (bombesin receptor subtype 3/BRS-3). Bombesin itself binds both BB1 and BB2 with high affinity, while GRP is selective for BB2.

In normal physiology, GRP is widely distributed in the central nervous system and gastrointestinal tract, where it stimulates gastrin release from G cells, promotes smooth muscle contraction, modulates gastric acid secretion, regulates pancreatic enzyme release, and participates in circadian rhythm regulation and thermoregulation. In the CNS, bombesin/GRP acts as a satiety signal, reducing food intake when administered centrally.

The oncological significance of the GRP/GRPR axis was recognized when GRPR overexpression was documented in prostate cancer (63-100% of primary tumors), invasive breast cancer (approximately 65-75%), small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) adenocarcinomas. Critically, GRPR expression in prostate cancer is present at all stages including early-stage disease, and appears to be inversely correlated with androgen receptor signaling — making it a valuable target even in castration-resistant prostate cancer (CRPC) where PSMA expression may be heterogeneous.

Mechanism of Action

Bombesin and GRP activate multiple signaling cascades through BB2/GRPR:

• Gq/11-coupled phospholipase C activation: GRPR activates PLC-beta, generating IP3 and DAG. IP3 mobilizes intracellular calcium from ER stores, activating calcium-dependent signaling. DAG activates protein kinase C (PKC), which phosphorylates downstream effectors including Raf-1 and MEK, driving MAPK/ERK proliferative signaling. Jensen, R. T. et al. (2008) — Biochim. Biophys. Acta

• Transactivation of receptor tyrosine kinases: GRP/GRPR signaling transactivates EGFR, HER2, and IGF-1R through matrix metalloproteinase (MMP)-mediated release of EGF-like ligands (amphiregulin, HB-EGF) and through Src-mediated direct phosphorylation. This RTK transactivation amplifies proliferative and survival signaling beyond what GPCR activation alone would produce. Thomas, S. M. et al. (2005) — Cancer Res.

• PI3K/Akt survival signaling: GRPR activates PI3K through Gbetagamma subunits and through RTK transactivation, increasing Akt phosphorylation and promoting cell survival through inhibition of pro-apoptotic factors (Bad, caspase-9) and activation of mTOR.

• Autocrine/paracrine growth loop in SCLC: Small cell lung cancer cells produce and secrete GRP/bombesin-like peptides that act as autocrine growth factors. Anti-bombesin monoclonal antibodies (2A11) inhibited SCLC xenograft growth in preclinical models, validating the autocrine loop concept. Cuttitta, F. et al. (1985) — Nature

• Angiogenesis promotion: GRP/GRPR signaling upregulates VEGF expression in tumor cells through HIF-1alpha-dependent and independent pathways, promoting tumor neovascularization.

• GI motility and secretory effects: In the gastrointestinal tract, bombesin/GRP stimulates gastrin release from antral G cells (triggering gastric acid secretion), cholecystokinin release from I cells, smooth muscle contraction in the stomach and colon, and pancreatic enzyme and bicarbonate secretion. McDonald, T. J. et al. (1979) — Gut

• Appetite and satiety regulation: Intracerebroventricular bombesin/GRP reduces food intake in rodents and primates through hypothalamic and brainstem satiety circuits. Peripheral bombesin administration also reduces meal size through vagal afferent signaling. BB3 (BRS-3) knockout mice develop obesity, suggesting this orphan receptor plays a role in energy homeostasis. Ladenheim, E. E. et al. (2002) — Am. J. Physiol. Gastrointest. Liver Physiol.

Reconstitution Calculator

Research

Safety Profile

Bombesin itself is not used therapeutically; safety considerations pertain to radiolabeled bombesin analogs and GRPR-targeting agents. Bombesin agonist-based tracers produce transient pharmacological effects including nausea, abdominal cramping, flushing, and urgency — reflecting GRPR-mediated GI stimulation. These effects are largely eliminated with antagonist-based tracers (RM2 and derivatives), which is a key advantage of the antagonist design philosophy.

For diagnostic 68Ga-RM2 PET/CT, the radiation dose is comparable to other PET tracers (effective dose ~3-5 mSv per injection). No significant adverse reactions have been reported in clinical studies. Renal uptake is the primary organ dose concern, though kidney accumulation is lower with GRPR-targeted peptides than with many SSTR-targeted agents.

For therapeutic 177Lu-RM2, dose-limiting toxicities are anticipated to mirror those of 177Lu-DOTATATE (PRRT): bone marrow suppression (thrombocytopenia, lymphopenia) and nephrotoxicity. Amino acid co-infusion (lysine/arginine) for renal protection is standard practice. Early-phase clinical data show manageable hematologic toxicity. Pancreatic uptake of GRPR-targeted agents is a theoretical concern due to normal GRPR expression in acinar cells, but clinically significant pancreatitis has not been reported.

BRS-3 agonists (MK-5046) in obesity trials produced blood pressure elevation and heart rate increases, leading to discontinuation of clinical programs.

Clinical Research Protocols

• 68Ga-RM2 PET/CT (prostate cancer imaging): 150-200 MBq (4-5 mCi) IV injection, imaging at 50-70 minutes post-injection. No special patient preparation required. Fasting not mandatory but recommended. Furosemide 20 mg IV at injection time to enhance bladder clearance.
• 177Lu-RM2 PRRT (investigational — mCRPC): Dose escalation protocols: 3.7-7.4 GBq per cycle, up to 4-6 cycles at 8-week intervals. Renal protective amino acid infusion (lysine 25g + arginine 25g IV over 4 hours). CBC and renal function monitoring weekly for first cycle, then pre-each cycle.
• Bombesin satiety studies (research): Bombesin 4-16 pmol/kg/min IV infusion. Meal test paradigm: 30-minute infusion before ad libitum meal, measuring caloric intake and subjective satiety (VAS). Blood sampling for CCK, gastrin, insulin at 15-minute intervals.
• GRPR expression assessment: OctreoScan is not useful (different receptor). Immunohistochemistry with anti-GRPR antibody on biopsy tissue. 68Ga-RM2 PET/CT uptake serves as in vivo biomarker of GRPR density.

Pharmacokinetic Profile